JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

Home・Akcijų sąrašas・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

25 -0.79

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

24.83

Max

25.33

Pagrindiniai rodikliai
By Trading Economics
Pajamos	675K 53M
Pardavimai	1.8M 148M
P/E Sektoriaus vid.	14.62 84.243
Pelno marža	35.57
Darbuotojai	181
EBITDA	1.7M 80M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+36% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-25

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	449M 3.1B
Ankstesnė atidarymo kaina	25.79
Ankstesnė uždarymo kaina	25

Naujienos nuotaikos

By Acuity

100%

337 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

N/A / 24.28 Palaikymas ir pasipriešinimas

Catalyst Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-03 23:11; UTC

Pagrindinės rinkos jėgos

Įsigijimai, susijungimai, perėmimai

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

2026-02-03 23:50; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-03 23:50; UTC

Rinkos pokalbiai

Nikkei May Decline After Hitting All-Time High -- Market Talk

2026-02-03 23:42; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Technical Correction -- Market Talk

2026-02-03 23:41; UTC

Įsigijimai, susijungimai, perėmimai

KKR Makes AI Play With $10.9B Asia Data-Center Deal

2026-02-03 23:38; UTC

Uždarbis

AMD Sales Climb on Help From Data-Center Business -- Update

2026-02-03 23:29; UTC

Įsigijimai, susijungimai, perėmimai

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

2026-02-03 23:27; UTC

Įsigijimai, susijungimai, perėmimai

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

2026-02-03 23:25; UTC

Įsigijimai, susijungimai, perėmimai

KKR-Consortium Expects Deal to Close by Early 2H of 2026

2026-02-03 23:23; UTC

Įsigijimai, susijungimai, perėmimai

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

2026-02-03 23:22; UTC

Įsigijimai, susijungimai, perėmimai

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

2026-02-03 23:19; UTC

Rinkos pokalbiai

Australia Gold Miners Tipped to Rally Higher -- Market Talk

2026-02-03 23:19; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-02-03 22:56; UTC

Pagrindinės rinkos jėgos

Įsigijimai, susijungimai, perėmimai

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

2026-02-03 22:40; UTC

Uždarbis

Amdocs Extends Collaboration With T-Mobile

2026-02-03 22:39; UTC

Uždarbis

Amdocs 1Q Adj EPS $1.81

2026-02-03 22:39; UTC

Uždarbis

Amdocs 1Q Rev $1.16B

2026-02-03 22:39; UTC

Uždarbis

Amdocs 1Q EPS $1.45 >

2026-02-03 22:38; UTC

Uždarbis

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

2026-02-03 22:30; UTC

Įsigijimai, susijungimai, perėmimai

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

2026-02-03 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

2026-02-03 22:14; UTC

Uždarbis

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

2026-02-03 22:13; UTC

Uždarbis

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

2026-02-03 22:12; UTC

Uždarbis

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

2026-02-03 22:10; UTC

Uždarbis

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

2026-02-03 22:10; UTC

Uždarbis

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

2026-02-03 22:10; UTC

Rinkos pokalbiai

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

2026-02-03 22:10; UTC

Uždarbis

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

2026-02-03 22:09; UTC

Uždarbis

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

2026-02-03 22:09; UTC

Uždarbis

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Akcijų palyginimas

Kainos pokytis

Catalyst Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

36% į viršų

12 mėnesių prognozė

Vidutinis 34 USD 36%

Aukščiausias 35 USD

Žemiausias 33 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Catalyst Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Catalyst Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

N/A / 24.28Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Rinkos nuotaikos

By Acuity

337 / 352 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.